This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo
Clinical Summary

Weight Changes After Diabetes Diagnosis and Risk of CVD, Mortality

Takeaway

  • Both weight loss and weight gain after type 2 diabetes (T2D) diagnosis by screening were associated with increased risk of all-cause mortality, but not cardiovascular disease (CVD) events, particularly in individuals without obesity.

Why this matters

  • Findings suggest that weight loss may differently affect people with T2D dependent on body mass index (BMI).
  • Personalisation of weight loss advice and support may be warranted.

Study design

  • This was an observational analysis of the ADDITION-Europe trial including 2730 adults with screen-detected T2D from the UK, Denmark and the Netherlands.
  • Associations between changes in weight 5 years following T2D diagnosis and incident CVD events (n=229) and (n=225) mortality up to 10 years after diagnosis were evaluated.
  • Funding: Medical Research Council.

Key results

  • Weight loss in the year after T2D diagnosis (weight loss ≥5% with regain: HR, 2.72; 95% CI, 1.17-6.30) and weight gain >2% (HR, 3.18; 95% CI, 1.30-7.82) correlated with a greater risk of all-cause mortality vs maintained weight.
  • Weight loss ≥5% that was maintained was associated with all-cause mortality (HR, 2.47; 95% CI, 0.99-6.21).
  • Weight loss ≥10% in the 5 years following T2D diagnosis was associated with a higher risk of all-cause mortality (HR, 2.04; 95% CI, 1.17-3.55).
  • This association was strong in those with BMI <30 kg/m2 (HR, 4.62; 95% CI, 1.87-11.42).
  • Associations of 1- and 5-year weight changes with CVD incidence were inconclusive.

Limitations

  • Study could not distinguish between intentional and unintentional weight loss.
 

Strelitz J, Sharp SJ, Khunti K, Vos RC, Rutten GE, Webb DR, Witte DR, Sandbaek A, Wareham NJ, Griffin SJ. Association of weight loss and weight loss maintenance following diabetes diagnosis by screening and incidence of cardiovascular disease and all-cause mortality: an observational analysis of the ADDITION-Europe trial. Diabetes Obes Metab. 2020 Dec 2 [Epub ahead of print]. doi: 10.1111/dom.14278. PMID: 33269535View abstract

This clinical summary originally appeared on Univadis, part of the Medscape Professional Network.

YOU MAY ALSO LIKE